BioNTech Earnings Shocker: Posts Lower Than Expected Q2 Profits, Revenues Fall

Loading...
Loading...
  • BioNTech SE BNTX has reported Q2 FY22 revenues of €3.19 billion, down from €5.3 billion a year ago and €6.37 billion in Q1 FY22.
  • BioNTech believes the development of the pandemic remains dynamic, causing a re-phasing of orders and leading to fluctuations in quarterly revenues. 
  • This revenue fluctuation caused by the re-phasing of orders is expected to remain over the rest of the financial year with uptake in demand in key markets in Q4 FY22 related to the Omicron-adapted bivalent vaccine, subject to regulatory approval. 
  • Related: EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters.
  • EPS of €6.45 ($6.872) missed the consensus of $7.36.
  • The company and its partner Pfizer Inc PFE signed an agreement with the U.S. government to provide additional 105 million doses of COVID-19 vaccine with an option for another 195 million doses.
  • BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of omicron in August.
  • Outlook: BioNTech reaffirms FY22 COVID-19 vaccine revenues of €13 billion - €17 billion as the doses scheduled for delivery in June through August will now be delivered in September through to Q4 FY22.
  • BioNTech has started manufacturing bivalent Omicron BA.1- and BA.4/5-adapted vaccines and expects to be able to start delivering shots targeted at BA.4 and BA.5 as early as October if it receives regulatory approval.
  • Price Action: BNTX shares are down 4.98% at $173.99 during the premarket session on the last check Monday.
  • Photo by x3 from Pixabay
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...